Experimental Drugs for the Treatment of Hepatitis D.
HBV/HDV coinfection
bulevirtide
hepatitis delta
interferon
lonafarnib
Journal
Journal of experimental pharmacology
ISSN: 1179-1454
Titre abrégé: J Exp Pharmacol
Pays: New Zealand
ID NLM: 101530345
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
12
2020
accepted:
23
02
2021
entrez:
23
4
2021
pubmed:
24
4
2021
medline:
24
4
2021
Statut:
epublish
Résumé
Chronic hepatitis D virus infection is the most severe form of viral hepatitis. Antiviral treatment is urgently needed to prevent patients from developing end stage liver disease or hepatocellular carcinoma. Treatment options were limited to off-label use of pegylated interferon alfa until conditional approval of bulevirtide by the EMA (European Medicines Agency) in July 2020. However, several other antiviral compounds are currently investigated and represent promising agents for the treatment of chronic HDV infection.
Identifiants
pubmed: 33889032
doi: 10.2147/JEP.S235550
pii: 235550
pmc: PMC8057838
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
461-468Informations de copyright
© 2021 Sandmann and Cornberg.
Déclaration de conflit d'intérêts
MC has received personal fees from AbbVie, Gilead Sciences, GSK, Janssen-Cilag, MSD Sharp & Dohme, Novartis, Spring Bank Pharmaceuticals, Swedish Orphan Biovitrum AB (SOBI). The authors report no other conflicts of interest in this work.
Références
Hepatology. 2020 Oct;72(4):1177-1190
pubmed: 32145073
J Infect Dis. 2018 Mar 28;217(8):1184-1192
pubmed: 29425306
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Gastroenterology. 2014 Apr;146(4):1070-83
pubmed: 24361467
J Infect Dis. 2020 Apr 27;221(10):1677-1687
pubmed: 31778167
Hepatology. 2014 Jul;60(1):87-97
pubmed: 24585488
Immunity. 2019 Apr 16;50(4):907-923
pubmed: 30995506
J Hepatol. 2014 Dec;61(6):1238-46
pubmed: 25064437
Lancet Infect Dis. 2019 Mar;19(3):275-286
pubmed: 30833068
N Engl J Med. 2011 Jan 27;364(4):322-31
pubmed: 21268724
Lancet. 2011 Jul 2;378(9785):73-85
pubmed: 21511329
J Infect Dis. 1987 May;155(5):931-5
pubmed: 3559292
Clin Gastroenterol Hepatol. 2015 Dec;13(13):2342-49.e1-2
pubmed: 26044319
Hepatology. 2018 Apr;67(4):1224-1236
pubmed: 29152762
Lancet Infect Dis. 2015 Oct;15(10):1167-1174
pubmed: 26189433
J Hepatol. 2020 Sep;73(3):523-532
pubmed: 32335166
J Hepatol. 2020 Sep;73(3):533-539
pubmed: 32151618
Antiviral Res. 2016 Sep;133:32-40
pubmed: 27400989
Gut. 2000 Mar;46(3):420-6
pubmed: 10673308
JAMA. 2014 Nov 12;312(18):1927-8
pubmed: 25387192
Science. 1992 May 29;256(5061):1331-3
pubmed: 1598578
J Hepatol. 2020 Mar;72(3):539-557
pubmed: 31730789
Liver Int. 2012 Oct;32(9):1415-25
pubmed: 22716112
J Hepatol. 2016 May;64(5):1011-1019
pubmed: 26739688
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Hepatol. 2019 May;70(5):1008-1015
pubmed: 30982526
Aliment Pharmacol Ther. 2020 Jan;51(2):231-243
pubmed: 31840863
Lancet Gastroenterol Hepatol. 2017 Dec;2(12):877-889
pubmed: 28964701
Hepatology. 2017 Feb;65(2):414-425
pubmed: 27770553